The remission of rheumatoid arthritis during pregnancy by Østensen, Monika & Villiger, Peter
REVIEW
The remission of rheumatoid arthritis during pregnancy
Monika Østensen & Peter M. Villiger
Received: 15 February 2007 /Accepted: 28 March 2007 / Published online: 27 April 2007
# Springer-Verlag 2007
Abstract Rheumatoid arthritis (RA) is an autoimmune
disease that is favorably influenced by pregnancy but relapses
after delivery. A variety of circulating factors has been
considered as candidates for inducing gestational improve-
ment of RA; however, the factors/pathways responsible
remain still elusive. This review discusses recent research on
the effect of pregnancy on RA with a focus on immunregu-
lation, cytokine secretion, HLA antigens, microchimerism,
and innate immunity. The complex hormonal and immuno-
logical alterations of pregnancy may temporarily correct the
disturbed immunregulation of RA.
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Pathology of RA
Rheumatoid arthritis (RA) is in an autoimmune chronic
inflammatory disorder of unknown etiology occurring in 1–
2% of the population. RA is associated with certain HLA class
II molecules that presumably interact with T cells. The
frequency of HLA-DRB1 genes that encode for the so-called
shared epitope, an amino acid motif in the third hypervariable
chain of the DRβ1 chain, is increased in RA patients [1]. RA
is characterized by symmetrical polyarthritis and extra-
articular manifestations including subcutaneous nodules, lung
disease, pericarditis, neuropathy, and vasculitis. About three
times more women are affected from RA than men. The
etiology of RA is still unknown. One of the major features of
RA is the presence of rheumatoid factor and of anticitrulli-
nated protein antibodies [1]. The synovium, the main target
of the inflammation seen in RA, is infiltrated by T cells, B
cells, and macrophages. Autoantigen recognition by specific
T cells seems to be a crucial event in RA [2]. The early stages
of RA are dominated by activated T cells (30–50% in the
synovia), mainly of the CD4+ T helper type. Failure of
regulatory T cells to control autoimmune effector T cells may
contribute to the chronicity of joint inflammation. In addition,
recent results about the remission inducing effect of B cell-
depleting antibodies argue for a central role of B lymphocytes
as well [3]. The chronic stage of arthritis is characterized by
the presence of macrophages and their products. Uncon-
trolled chronic inflammation of joints results in the destruc-
tion of cartilage and bone [4]. There is evidence for the
dominance of T helper cell type 1 (Th1) cytokines in early
stages of RA [5]. Later, T helper cell type 2 (Th2) features
emerge, probably as a counter-regulatory effort of the
immune system. Regarding clinical signs and typical findings
such as synovitis and joint destruction (bony erosions and
cartilage thinning), certain cytokines play central roles: tumor
necrosis factor α (TNFα), interleukin 1 (IL-1), and IL-6.
With the help of blocking strategies it could be proofed that
the TNFα and IL-6 pathways are of central importance, while
blockage of IL-1β using the natural receptor antagonist was
less effective [6]. It remains to be defined whether other
proinflammatory cytokines play essential or contributory
roles in the pathogenesis of this autoimmune disease.
The effect of pregnancy on disease activity in women
with RA
Pregnancy exerts a beneficial effect on the symptoms and
signs of RA [7]. Both retrospective and prospective studies
comprising more than 500 pregnancies have shown that
about 75% (range 54–86%) of patients experience im-
provement or even remission of arthritis during gestation
[8–10]. Improvement occurs for 50–76% of patients already
at the end of the first trimester and is usually sustained
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throughout pregnancy. Symptoms of joint inflammation are
either improved or completely suppressed rendering thera-
py unnecessary. Within 3 months after delivery, a relapse is
observed in 90% of patients [10].
The risk of early or late miscarriage is not increased in
RA. Except for a slight increase in prematurity and
intrauterine growth restriction in patients with active
disease, the course of pregnancy and outcome is favorable
in RA [11, 12]. Thus, there is no indication for the disease
process of RA to disturb fertilization, implantation, or
placental function except in severely ill patients.
The pregnancy-induced amelioration and postpartum
relapse of RA
A variety of biochemical and immunological changes take
place in pregnancy. The mechanisms by which tolerance to
the semiallogeneic fetus is established are truly involved in
the suppression of autoimmunity during pregnancy. A
number of circulating factors has been considered in the
pregnancy-induced amelioration of RA [13]. As a rule,
these were proteins that had shown immunosuppressive
properties in-vitro like suppression of T cell activation and
proliferation or inhibition of the mixed lymphocyte culture
[14]. Among the candidate factors studied, neither in-
creased serum cortisol concentrations, elevated levels of sex
hormones, pregnancy-associated α-2 globulin, nor reversal
of abnormalities in the percentage of IgG immunoglobulins
lacking the terminal galactose emerged as a convincing
explanation for improvement of RA during pregnancy [13,
15–18] (Table 1). Given the fact that the survival of the
fetus is secured by a redundancy of protective mechanisms,
the factor(s) responsible for the gestational remission of RA
still remain(s) elusive. A main difficulty is to separate
primary events crucial for an effect on RA from secondary
phenomena that occur further downstream. Clues emerge as
more pathogenetic mechanisms of RA are revealed.
After delivery, the maternal system adjusts again to the
nonpregnant state. The postpartum flare of RA could be
viewed as a kind of withdrawal symptom related to the
decrease in steroid hormones [19], the re-establishment of a
Th1-dominated immune response, and the unopposed
action of proinflammatory cytokines [20].
Alteration of the immune response in pregnancy
Pregnancy induces changes in the maternal immune system
to protect the fetus from immunologic attack by the mother.
There are several excellent reviews on this topic [21, 22]. In
the context of RA characterized by a Th1-type immune
response, the shift to a type-Th2 response during pregnancy
is of interest [23]. Interferon γ (IFN-γ), IL-12, TNFα, and
IL-1 are proinflammatory cytokines that contribute to
synovitis and joint destruction in RA [4]. During pregnan-
cy, cytokines of the Th2-type immune response like IL-4
and IL-10 have been shown to prevail and, as a conse-
quence, suppress inflammation [20].
Studies of maternal serum levels of cytokines and their
receptors have shown that an increase in IL-1 and IL-6 is
observed parallel with an increase in their receptors [24].
Soluble TNF receptors (sTNFRs) increase throughout
pregnancy [25]. In one study, the inhibitors of the proin-
flammatory cytokines IL-1 and TNFα, the IL-1 receptor
antagonist, as well as the sTNFR-75 were elevated in late
stages of pregnancy both in pregnant patients with rheu-
matic disease and in healthy pregnant women [26]. How-
ever, the cytokines measured in the maternal circulation
showed no pattern typical for a Th2 response. Collectively,
these results argue for a pregnancy-induced up-regulation of
anti-inflammatory mechanisms, which in turn counteract the
inflammatory process of RA.
A shift to a TH2 cytokine profile is observed in peripheral
lymphocytes in pregnancy. Activation of peripheral T cells
has been shown by demonstrating an increase both in IFN-
γ- and IL-4-secreting cells [27]. The ratio of IFNγ/IL-4
decreases as a reflection of the shift to a Th2 response
[27]. This still promotes a Th2 response because high levels
of IL-4 dominate over IFN-γ effects. Elevated levels of
Table 1 Overview over various proteins investigated as candidates of disease remission in RA
Factor studied Effect on disease activity References
Cortisol Anti-inflammatory. Induces a Th2 cytokine pattern and production of TGFβ.
No clear association to disease activity in pregnancy
[15, 19, 20]
Estrogen Estradiol reduces cytotoxocity of T cells, induces Treg, and potentiates
their suppressive activity. Beneficial effect of pregnancy on disease activity
[34, 36, 37]
Pregnancy-associated
α-2 globulin
Suppression of lymphocyte activation, phagocytosis and chemotaxis. Inverse
relationship between RA disease activity and PAG levels in two studies
[16, 17]
a-Galactosyl immuno
globulin G
Normalization of galactosylation of IgG during pregnancy renders IgG less antigenic.
An increase in galactosylated IgG was correlated to low disease activity of RA
during pregnancy
[18]
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mRNA expression for IL-10 and an increase in IL-10
secretion were found in peripheral blood mononuclear cells
of four pregnant RA patients studied prospectively during
and after pregnancy [28]. A study of monocytes isolated
from third-trimester pregnant women showed significantly
reduced production of TNFα and IL-12 compared to
postpartum [29]. Thus, on the cellular level, there is indeed
a predominance of a Th2 cytokine pattern with an increase in
IL-4 and IL-10 that antagonize the proinflammatory cyto-
kines involved in the pathology of RA. The beneficial effect
of pregnancy on RA may be a down-regulation of a Th1
response rather than an up-regulation of the Th2 response.
Hormones in pregnancy
Pregnancy induces changes in the whole neuroendocrine
system, and interactions occur in a very complex manner.
Cells involved in immunoinflammatory events express recep-
tors for cortisol and sex steroid hormones, and thus, hormones
modulate immune responses. There is a progressive rise in total
plasma cortisol levels with advancing gestation [30]. Both the
bound and unbound fractions of cortisol increase as well as
the cortisol-binding globulin. The free, active form of cortisol
reaches about twice its plasma concentration compared to the
nonpregnant state. One of the reasons for the increase is high
levels of estrogen, which decrease the metabolic clearance of
cortisol. The increase in cortisol is most marked in the first
half of pregnancy but remains elevated throughout pregnancy.
Together with sex steroids, glucocorticoids promote a Th2
response and are the most potent inhibitors of proinflamma-
tory cytokines like IL-1, IL-6, IL-2, IFN-γ, and TNFα [20,
31]. Furthermore, glucocorticoids induce the production of
transforming growth factor β, which in turn is an antagonist
of proinflammatory cytokines.
RA patients show a relative corticosteroid deficiency and an
impaired response to corticosteroids [32, 33]. It was, therefore,
originally believed that the gestational rise of plasma cortisol
alone could explain the gestational improvement of RA.
Studies in the 1960s, however, showed no convincing
correlation between corticosteroid levels measured in preg-
nancy and disease activity [15]. In addition, improvement of
RA is observed in the first trimester in about 75% of the
patients, at a time when free cortisol levels are still low [8].
Pregnancy-associated concentrations of estrogens, proges-
terone, and glucocorticoids may collectively promote an anti-
inflammatory environment. Sex hormones can block some
important mechanisms involved in the development of RA,
including immunoregulation, inflammatory response, cyto-
kine secretion, and cartilage damage [34]. Estradiol has
shown a protective effect on cartilage preventing proteogly-
can degradation in arthritic mice [35]. Estrogens show a
biphasic effect with low concentrations activating and high
concentrations suppressing T cell functions. Low, nonpreg-
nant levels of estradiol stimulate IFN-γ production in T cells
[36]. High levels of steroid hormones during pregnancy have
discrete regulatory effects on the Th1/Th2 balance. Pregnan-
cy levels of estrogens induce secretion of IL-10 and suppress
TNFα production in T cells [31] as well as suppressing
cytotoxicity of T cells [37]. Progesterone enhances IL-4 and
IL-10 production in human T cells, thereby promoting the
expansion and differentiation of T helper cells with a TH2-
type cytokine response [31]. Lymphocytes develop proges-
terone receptors during pregnancy and release a protein
named progesterone-induced blocking factor (PIBF) [38].
PIBF has a strong anti-natural killer (NK) cell activity, and
PIBF-positive lymphocytes secrete IL-10 [39].
It has been hypothesized that autoimmune phenomena in
the postpartum period could be associated with low hypotha-
lamic secretion of the corticosteroid-releasing hormone, which
remains suppressed for about 3 months [40]. The question if
the resulting, relative hypocortisolism is involved in postpar-
tum aggravation of RA remains unanswered. The timing of
the postpartum flare does not coincide with the return of
cortisol plasma levels to normal 2–5 days after delivery.
Furthermore, treatment with glucocorticoids postpartum does
not prevent a flare [41]. Prolactin has been proposed to play a
role in the postpartum relapse of RA [42]. Some studies have
found an association between breast-feeding, a state with
elevated prolactin levels, and disease relapse of RA [42].
Hypophysectomized mice did not develop adjuvant arthritis
unless they were treated with prolactin [43].
Regulatory T cells
Several subsets of regulatory T cells (Treg) have been
identified [44]. Treg have a key role in the maintenance of
immune tolerance to both self and foreign antigens. Treg
suppress activation and proliferation of conventional T cells
and are able to suppress autoimmunity. In the following, we
discuss data published on CD4+CD25+forkhead family
transcription factor 3 (Foxp3)+ Treg because they are the
most studied in RA.
CD4+CD25+ Treg
Depletion and reconstitution experiments in mice have shown
that CD4+CD25+ T cells can prevent or ameliorate autoim-
mune disease like diabetes or collagen-induced arthritis [45].
CD4+CD25+ Treg inhibit both the activation and prolifera-
tion of autoreactive CD4+ T cells in an Ag-nonspecific
fashion that is contact dependent but cytokine independent
[46]. The expression of Foxp3 is regarded a characteristic of
CD4+CD25+ Treg and differentiates them from activated
CD4+ T cells [47]. Numbers of CD4+CD25+ Treg are
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reduced in peripheral blood [48] but elevated in the inflamed
synovium of RA patients and of juvenile idiopathic arthritis
(JIA) [49, 50]. However, synovial responder T cells show
decreased susceptibility to the regulatory effect of Treg cells
and fail to respond with a Th2-type cytokine secretion in
coculture [51]. The presence of TNFα in arthritis inflam-
mation may be responsible for the down-regulation of the
CD4+CD25+ Treg suppressive function [52]. Interestingly, a
correlation between high numbers of Treg locally and
sustained remission of arthritis was observed in JIA [50].
An increase in CD4+CD25+ Treg in peripheral blood has
been found after successful therapy in RA [51].
An expansion of CD4+CD25+ Treg has been demonstrat-
ed in mice during syngeneic and allogeneic pregnancy [53]. In
healthy pregnant women, CD4+CD25+ Treg increase rapidly
in peripheral blood peaking at midgestation and decreasing
after delivery [54, 55]. Interestingly, expansion of Treg is
driven by pregnancy levels of estradiol, which induce Foxp3
in CD4+CD25+ T cells [56]. One study found the
suppression of proliferation of responder T cells by Treg
markedly enhanced in the presence of estradiol [57].
HLA antigens, maternal–fetal incompatibility
and microchimerism
The fetal cells coming into direct contact with maternal cells
in the uterus do not express classical human leucocyte
antigens (HLA) class I or class II genes. However, HLA-DR
protein has been recently identified within the cytoplasm of
the shed trophoblast [58]. To escape both cytotoxic T cells
and attack by NK cells, trophoblast cells express nonclassical
major histocompatibility complex (MHC) class I antigens:
HLA-E, HLA-F, and HLA-G [22]. HLA-G exists in several
isoforms, four membrane bound and three soluble, and
seems to play a major role in promoting maternal tolerance to
the fetus [59]. HLA-G inhibits activating signals on
leucocytes by binding to leucocyte inhibitory receptors.
Elevated levels of soluble HLA-G (sHLA-G) are found in
maternal circulation during pregnancy. Functional studies of
HLA-G have shown inhibition of NK cytolysis, down-
regulation of IFN-γ and TNFα, and induction of a Th2
cytokine profile and of suppressive, regulatory T helper cells
[60]. sHLA-G can also induce apoptosis of activated T cells.
Maternal–fetal incompatibility
A number of observations suggest that HLA incompatibility
between mother and child is advantageous for the outcome of
pregnancy [61]. Collagen-induced arthritis in mice improves
much more in allogeneic than in syngeneic pregnancy [62].
Furthermore, HLA incompatibility induces a stronger Th2
cytokine response with more secretion of IL-4 and IL-10 [63].
In 1993, Nelson et al. [64] studied 46 pregnancies and found
that disparity at the HLA-DRB1, DQA1, and DQB1 alleles
between mother and fetus corresponded in 26 out of 34
pregnancies to amelioration or remission in RA. A Dutch
study of 33 pregnancies in 1998 confirmed that maternal–
fetal incompatibility at the DQA1 and DQB1 locus influenced
the course of RA favorably during pregnancy [65]. A third
study typed 118 maternal–fetal pairs from RA pregnancies for
HLA-DRB1 and DQB1 but found no influence of HLA
incompatibility on disease activity [66]. The disagreement
between the studies may partly be based on different design
and evaluation of disease activity of RA patients. Mecha-
nisms proposed for the effect of maternal–fetal HLA disparity
on disease activity of RA were: HLA class II molecules
present foreign antigen but also self-antigens. In mothers with
RA, peptides derived from class II HLA antigens of the fetus
might compete with self-antigens and divert the mother’s
immune response away from an autoimmune response.
During pregnancy, fetal cells escape into the maternal
circulation. Several studies have shown that they remain for
decades in the mother, perhaps indefinitely. It has recently
been established that fetal cells and cell-free DNA routinely
traffic into the maternal circulation during normal pregnan-
cy [67] and can be detected in the maternal serum as early
as the first trimester. The concentration of fetal DNA
increases over the course of pregnancy and declines rapidly
after delivery [68]. The role of fetal cells or fetal DNA is
not quite clear. Induction of tolerance to paternal antigens
in the mother or the induction of a Th2 response could be
possible results. The viewpoint has been put forward that
altered peptide–MHC complexes can deviate development
of T helper subsets away from Th1 and select for Th2 [69].
Interestingly, studies investigating the response of maternal
peripheral blood mononuclear cells to trophoblast or
paternal HLA antigens showed that paternal antigens
stimulated the production of IL-4 [70].
In a recent study, a significant inverse correlation
between arthritis activity and serum fetal DNA concen-
trations was found over the course of pregnancy and
postpartum [71]. Arthritis amelioration occurred in 79%
of patients with RA over a similar time course as rising
serum fetal DNA levels, increasing as pregnancy pro-
gressed and dropping to undetectable or low levels after
delivery, coincident with arthritis recurrence. In the third
trimester, serum levels of fetal DNA were significantly
greater in patients with amelioration as compared to those
with active disease.
A recent review has suggested that shed trophoblast and
apoptotic fetal cells in the maternal circulation may be
crucial players in the remission of RA observed during
pregnancy [72]. Apoptosis of fetal cells or placental
trophoblast cells will release fetal HLA alloantigens. The
uptake and cross-presentation of soluble fetal paternally
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inherited HLA peptides and self-HLA class II peptides in
the environment of pregnancy could modulate the maternal
autoimmune response of RA. Suppression of autoreactive T
cells could be achieved by T cell deletion, anergy, or by
induction of Treg. With the removal of the placenta after
parturition, the source of trophoblast debris or fetal DNA
disappears resulting in the reappearance of an autoimmune
response. As shown in the study by Yan et al. [71], the drop
of serum fetal DNA after delivery was coincident with the
relapse of arthritis.
Innate immunity
The mother is not systemically immunosuppressed nor
immunodeficient. However, specific immune responses are
weakened during pregnancy. The suppression of the adaptive
immune response is compensated by activation of the innate
immune system. Granulocytes and monocytes are increased in
number during gestation [73]. It has been shown that
monocytes get activated through phagocytosis of debris shed
from the trophoblast, but in contrast to phagocytosis of other
particles, increased secretion of IL-10 and decreased secre-
tion of IL-1β follows [74]. Studies some 25 years ago and
several recent investigations explored the effect of pregnancy
on cells of the innate immune system. Results of studying the
activation status of granulocytes and monocytes from
pregnant women differ, some showing enhanced activation,
others demonstrating reduced activity during pregnancy. A
study of pregnant healthy women and of pregnant patients
with rheumatic disease found enhanced metabolic activity
and migration of granulocytes and monocytes in pregnancy
[75]. Another study observed an increase in the expression of
CD11b, CD14, and CD64 and CD32 on monocytes [76] in
pregnancy with a peak in the third trimester [77]. Enhanced
production of IL-12 was demonstrated in monocytes from
pregnant women [76]. Monocytes also displayed an in-
creased capacity for phagocytosis [77]. By contrast, several
studies of neutrophil function in pregnant women and
pregnant RA patients found decreased phagocytosis and
reduced neutrophil superoxide anion release in pregnancy
[73, 78]. Similar reduction in neutrophil responsiveness to
external stimuli was found in studies incubating neutrophils
with supraphysiological levels of estradiol [79]. The contra-
dictory results in regards to neutrophils are partly related to
the method used to measure superoxide anion production and
to the definition of neutrophil activation. As has been pointed
out, different results are obtained depending on whether
extracelullar release of reactive oxygen metabolites (ROM)
or intracellular release is measured [80]. Neutrophils of preg-
nant women show enhanced spontaneous intracellular ROM
release [80]. This can be defined as “activation,” whereas
stimulated extracelullar ROM release has been found
diminished, and this could be labeled as “suppression” of
neutrophil function [80].
Conclusion
The spontaneous improvement or remission of RA during
pregnancy remains an intriguing phenomenon that inspires
continuous research. The beneficial effect of pregnancy on
a disease that affects different organ systems must be
mediated by circulating factors, either proteins or traffick-
ing cells. Because the etiology of RA at present is not
known, one can only speculate on the importance of the
possible candidates presented in this review.
The crucial event of pregnancy is the implantation of the
fertilized egg and the resulting presence of a semiallogeneic
graft in the mother for 9 months. In spite of contact with
fetal cells, maternal T cells are tolerized to paternal
antigens. The presence of HLA antigens that differ from
maternal HLA class II antigens at the DQ loci have been
proposed as beneficial for the course of RA during
pregnancy. However, at present, the mechanisms by which
the ameliorating effect is achieved remains unclear. It seems
unlikely that HLA disparity between mother and fetus
promotes the expansion of Treg because the study of
Aluhivare et al. [53] showed the gestational increase in
CD4+CD25+ Treg both in syngeneic and allogeneic
pregnancies. Thus, expansion of Treg is not driven by fetal
alloantigens. However, maternal–fetal disparity could come
into play through induction of Th2-type cytokine secretion
in T cells, which is supported by the work of Chaouat et al.
[63]. The beneficial effect of counteracting the predomi-
nance of Th1-type cytokines has been convincingly shown
by the success of TNF-blocking agents in inflammatory
rheumatic disease. This suggests that any condition that
suppresses Th1 pathways can ameliorate activity of RA. In
pregnancy, the concerted action of hormones and of fetal cells
including the trophoblast promotes an anti-inflammatory
milieu not only at the maternal–fetal interface but also
systemically. The tolerizing effect of pregnancy is not
limited to adaptive immunity. Furthermore, monocytes and
neutrophils undergo changes that support their vigilance
but counteract a proinflammatory milieu.
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